Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to a 22% weight reduction in obese and overweight patients compared to a 2.0% weight gain in the placebo group. The trial showed promising results for amycretin, a treatment that targets the same gut and pancreas hormones as Novo Nordisk’s flagship obesity drug Wegovy and diabetes treatment Ozempic. Novo Nordisk is also developing an amycretin obesity pill, with early-stage trials demonstrating a 13.1% weight loss after 12 weeks and mild-to-moderate side effects.
Full Article
Judge blocks release of Epstein files where Trump reportedly named
A US judge has denied the unsealing of grand jury materials from the investigation into Jeffrey Epstein, citing Florida law, despite claims that US President Donald Trump’s name appears in related documents. The ruling, which emphasizes the need for grand jury secrecy, comes amid pressure on Trump for transparency in the case and ongoing political tensions surrounding Epstein's associates. Want More Context? 🔎
Read more